rbs morgan spec buy

Today's highlights
What you need to know today - Sirtex
Sirtex initiation of coverage report
Acrux - positive from a technical view
QRX Pharma - a  large bottom forms
Pfizer break up chatter continues
Mobile Helathcare to expand - look at Isonea (ISN)
Top potential drugs for 2013  
Funny bone
Milestone Timeline
Contacts
Scott Power
 07 3334 4884
[email protected]

Jack McManus
07 3334 4521
[email protected]

Tanya Solomon
[email protected]

What you need to know today

Sirtex initiation of coverage expands our universe.

Here is our coverage universe plotted against ASX200




RBS Morgans and CIMB Research
Sirtex (SRX, Neutral, Price Target A$13.00) - SIR-Spheres microspheres uptake has benefited from recent market development initiatives. While near-term momentum may continue, we view the real potential contingent on the outcome of five ongoing clinical studies due to report starting in 2015. We are cautious on trial success, but view current trading levels as adequately reflecting upside/downside risk. (Source derek Jellinek)
Acrux (ACR) from our Technical Analyst - The down trend channel from the June 2012 high has lost momentum over the past two months and the price has been trading sideways within the boundaries of a small ascending triangle pattern. The pattern has bullish implications and suggests that higher price levels are likely to unfold in the month(s) ahead. A break above resistance of $3.05 will confirm the pattern and trigger a buy signal. The potential upside price target is $3.45. Buy on a break above $3.05.
QRxPharma (QRX) - from our Technical Analyst - QRX has been trading sideways over the past six months, fluctuating within the boundaries of an ascending triangle pattern. Recent price action decisively broke above resistance of $0.92, confirming that a large bottom has been posted. The first potential upside price target based on the breakout is $1.34, however levels towards $1.50 are achievable over time. Any weakness in the short term should be considered a buying opportunity. MT: Buy.

Key stories
 
Any discussion on the near-term future of Big Pharma starts with a review of the top drugs in Phase III. And this year's crop includes a collection of some high-flying blockbuster prospects that has analysts encouraged enough to allow that the productivity gains seen over the last two years could translate into some big new approvals in 2013. But no one is breaking out the champagne bottles just yet. "The industry has done a lot to try and improve productivity and has corrected a lot of past mistakes," Deutsche Bank analyst Richard Parkes tells Reuters. "It's too early to say whether this is going to be a sustained break-out from the trend but the efforts that have been put in place should at least improve the efficiency of what is being spent." Reuters' two top biopharma scribes, Ben Hirschler and Bill Berkrot, have scanned the horizons and identified a slate of the top potential blockbusters now in Phase III. Their picks for leaders of the late-stage pack: Biogen Idec's ($BIIB) BG-12, a new MS drug expected to win regulatory approval and go on to sweep up much of the market with best-in-class potential. Johnson & Johnson (JNJ) makes it into the top tier with the SGLT2 diabetes drug canagliflozin, given a thumbs up at a recent advisory panel meeting with a good shot at penetrating a $7 billion market. The diabetes market may also be roiled by Novo Nordisk's ($NVO) long-acting insulin Tresiba while Novo attempts a separate blockbuster effort to get liraglutide OK'd for obesity. (Source: FierceBiotech)
 
Some Wall Street analysts must be giggling with glee today. A top Pfizer (PFE) official tells Bloomberg that the company will probably reorganize into two business units--one focused on innovative drugs, the other on off-patent meds (and perhaps consumer health)--from four. And that would pave the way for (insert giggle here) a two-way split. If you've been following CEO Ian Read's streamlining efforts over the past two years, you know that he's been shedding business units to zero in on Pfizer's core prescription drugs business, and to return cash to shareholders, a not-incidental goal. You also know that some analysts have championed even more streamlining, arguing that Pfizer would be worth more to investors if broken into smaller pieces. Pfizer has already sold its Capsugel unit. It's in the midst of unloading its nutrition business to Nestle. And it's begun the process of spinning off its animal health unit under the Zoetis name. But Pfizer still has a consumer health unit that some consider ripe for divestment. Another candidate is the "established products" business, i.e., off-patent drugs and generics. Or, perhaps, a combination of those two businesses, which Read calls the "value" side of the company.. (Source: FiercePharma)
 Driven by the increasing adoption of smartphones and rising incidences of chronic diseases, the global mHealth market will reach $10.2 billion by 2018 from the 2012 level of $1.3 billion, a compounded annual growth rate of 41.5 percent from 2012 to 2018, a new report from Albany, N.Y.-based Transparency Market Research finds. The firm, in a Jan. 8 announcement, said the most impactful trend witnessed in the global mHealth market is the growth in remote patient monitoring. In 2012, the monitoring services segment had the largest share of the mHealth market (63 percent), a trend that Transparency Market Research sees continuing. "The monitoring services segment will also be the fastest growing during the forecast period, owing to their usability in acute conditions such as coronary artery disease, hypertension, and congestive heart failure," the report states. "The contribution of monitoring services to the overall mHealth revenues will be greater in countries with higher income levels." Our comment - Buy - Isonea (ISN) it is a mobile health play focussed on asthma.  (Source: FierceMobileHealth


The funny bone...

What do you get if you cross a hospital with a skunk? A medical scenter.

Milestone Timeline



Disclosures: RBS Morgans Limited is a Lead Manager to the Sunshine Heart Inc. share placement (Tranche 2) and may receive fees in this regard. RBS Morgans Limited was the Joint Lead Manager to the QRxPharma Limited share placement and rights issue in July 2011 and may receive fees in this regard. RBS Morgans Limited was the Manager to the Phylogica Limited placement in March 2011 and received fees in this regard. RBS Morgans Corporate Limited is the Lead Manager and Underwriter to the Tissue Therapies Limited rights issue in April 2011 and may receive fees in this regard. An Executive of RBS Morgans Limited is a Director of Tissue Therapies Limited and will earn fees in this regard. RBS Morgans Corporate Limited was a participating broker in the Genetic Technologies Ltd share placement in April. RBS Morgans Corporate Limited is a Joint Lead Manager to the Phosphagenics Limited share placement and SPP in and may receive fees in this regard. RBS Morgans was a participating broker in the recent share placement in July 2011 and may receive fees in this regard. RBS Morgans Corporate Limited was Lead Manager and Underwriter to the Alchemia Limited share placement in November 2011 and received fees in this regard. RBS Morgans Corporate Limited is a lead manager to the ImpediMed Limited accelerated non-renounceable entitlement offer and may receive fees in this regard. RBS Morgans Corporate Limited was Lead Manager to the Allied Healthcare Group Limited placement and SPP in December 2012 and received fees in this regard. RBS Morgans Corporate Limited will be acting as Australian placement agent for the US IPO of Audeo Oncology Inc and will receive fees in this regard. Analyst owns shares in: ACL, ACR, SHC, QRX, IPD